Retinal Nerve Fiber Layer Thickness in Prediabetic Patients.
Journal
The Eurasian journal of medicine
ISSN: 1308-8734
Titre abrégé: Eurasian J Med
Pays: Turkey
ID NLM: 101557701
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
22
3
2022
Statut:
ppublish
Résumé
Diabetic retinopathy is a leading cause of blindness. Diabetic retinopathy is not only seen in diabetic patients with the clinical diagnosis but also in prediabetic patients. The aim of this study is to evaluate the RNFL thickness in prediabetic patients. In this study, 50 prediabetic patients and 50 healthy individuals were included. RNFL measurements were performed with SD-OCT in patients with prediabetes and healthy controls. The mean RNFL thickness for the prediabetic group was 94.7 ± 6.3 μm, inferior quadrant (120 ± 11.6), superior quadrant (112.3 ± 14.13), nasal quadrant (71 ± 12.9), and temporal quadrant (65.3 ± 9.2 μm). The mean RNFL thickness for the control group was 98.9 ± 7.5 μm, inferior quadrant (128 ± 14.7), superior quadrant (116.3 ± 15.12), nasal quadrant (77 ± 15.8), and temporal quadrant (71.2 ± 10.3 μm). Variance analysis demonstrated that the RNFL thickness difference between the groups was significant in all quadrants (P < .001). RNLF thinning can be seen in prediabetic patients before obvious vascular damage has occurred, and it may present in prediabetic patients not only in the temporal quadrant but also in all quadrants. The early retinal neural changes shown in this study in prediabetic patients may help to better understand the process leading to diabetic overt retinopathy.
Identifiants
pubmed: 35307621
doi: 10.5152/eurasianjmed.2022.20420
pmc: PMC9634872
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8-11Références
Diabetes Care. 2010 Nov;33(11):2355-9
pubmed: 20724649
J Glaucoma. 2013 Sep;22(7):532-41
pubmed: 22549477
Eur J Prev Cardiol. 2019 Dec;26(2_suppl):47-54
pubmed: 31766914
J Diabetes Complications. 2014 Jul-Aug;28(4):482-7
pubmed: 24630763
Invest Ophthalmol Vis Sci. 2011 Feb 28;52(2):1156-63
pubmed: 21357409
Ophthalmic Res. 2016;56(1):1-9
pubmed: 27035578
Diabetes Res Clin Pract. 2018 Apr;138:271-281
pubmed: 29496507
Mol Vis. 2018 May 18;24:353-366
pubmed: 29853770
Arch Physiol Biochem. 2018 Feb;124(1):75-79
pubmed: 28780883
Doc Ophthalmol. 2015 Oct;131(2):95-104
pubmed: 25972299
Int Ophthalmol. 2018 Aug;38(4):1621-1626
pubmed: 28733928
Indian J Ophthalmol. 2014 Jun;62(6):719-20
pubmed: 25005202
Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27
pubmed: 29222373
Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6433-7
pubmed: 26447978
Diabetes Care. 2019 May;42(5):875-882
pubmed: 30833368
Lancet Diabetes Endocrinol. 2015 Nov;3(11):866-75
pubmed: 26377054
Diabet Med. 2007 Feb;24(2):137-44
pubmed: 17257275
Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3660-5
pubmed: 20130282
Eye (Lond). 2012 Jun;26(6):816-20
pubmed: 22441028
Lancet. 2012 Jun 16;379(9833):2279-90
pubmed: 22683128